NCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
10 trialsNCT02915783 2023-01-17
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
Phase 2 Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02017860 2020-04-30
Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.
Novartis
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01122199 2017-05-10
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
Indiana University
Phase 1 Completed
NCT00936702 2017-03-21
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00597506 2012-12-27
BEV/EV
Duke University
Phase 2 Completed
NCT00496600 2012-06-14
Phase I Study of Patupilone and RAD001
Rutgers, The State University of New Jersey
Phase 1 Completed